The global market for Irritable Bowel Syndrome (IBS) Therapeutics was valued at US$2.3 Billion in 2024 and is projected to reach US$3.4 Billion by 2030, growing at a CAGR of 7.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Irritable Bowel Syndrome (IBS) Therapeutics market.
The treatment landscape for IBS has diversified over the years, moving beyond conventional options like fiber supplements and muscle relaxants to include tailored treatments based on predominant symptoms - ranging from dietary changes and probiotics to antibiotics and combinations of medications such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). There's a shifting emphasis from antispasmodics, due to their limited efficacy and significant side effects, towards TCAs and SSRIs that modulate pain perception both centrally and peripherally. Additionally, dietary management, particularly the reduction of high-FODMAP foods, and the use of probiotics have become integral in managing bloating and other digestive discomforts. For constipation and diarrhea predominant IBS, newer medications like lubiprostone and linaclotide for constipation, and alosetron and rifaximin for diarrhea, are enhancing therapeutic outcomes by targeting specific functional symptoms of the disorder.
Several factors are driving growth in the IBS therapeutics market. Advances in diagnostic technologies, such as the implementation of the Rome IV guidelines, have refined the accuracy of IBS diagnosis, fostering a more targeted therapeutic approach. There is also an increased consumer awareness and engagement, partly fueled by media, patient advocacy groups, and healthcare initiatives, which heighten demand for effective treatments. The integration of digital health solutions, including telehealth services and mobile health applications for symptom tracking and management, supports continuous patient monitoring and personalized treatment adjustments. Furthermore, the development of targeted pharmacological agents aimed at modifying gut flora, and expanding insurance coverage and healthcare policies that favor newer, albeit more costly, treatments are enhancing access to these therapies. These advancements, alongside active patient support programs and evolving regulatory landscapes, are essential for meeting the growing needs of IBS patients and improving their overall management and quality of life.
Segments: Type (IBS-D, IBS-C); Product (Linzess / Constella, Xifaxan, Viberzi, Amitiza, Other Products).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Irritable Bowel Syndrome (IBS) Therapeutics Market - Key Trends and Drivers Summarized
Irritable Bowel Syndrome (IBS) is a prevalent gastrointestinal disorder that affects the large intestine, manifesting symptoms such as abdominal pain, bloating, constipation, and diarrhea. Although not life-threatening, IBS substantially reduces quality of life and imposes a significant economic burden on healthcare systems. Historically, IBS was diagnosed by exclusion, but advancements now allow for quicker identification using criteria such as the Rome III, alongside a detailed medical history and physical examination. This disorder is characterized by chronic abdominal discomfort or pain associated with altered bowel habits, with symptoms needing to have started at least six months before diagnosis and occurring at least three days per month in the last three months. This contemporary understanding helps streamline the diagnostic process, avoiding unnecessary and costly tests, especially in younger patients presenting typical IBS symptoms without severe indicators such as unintentional weight loss or anemia.The treatment landscape for IBS has diversified over the years, moving beyond conventional options like fiber supplements and muscle relaxants to include tailored treatments based on predominant symptoms - ranging from dietary changes and probiotics to antibiotics and combinations of medications such as tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). There's a shifting emphasis from antispasmodics, due to their limited efficacy and significant side effects, towards TCAs and SSRIs that modulate pain perception both centrally and peripherally. Additionally, dietary management, particularly the reduction of high-FODMAP foods, and the use of probiotics have become integral in managing bloating and other digestive discomforts. For constipation and diarrhea predominant IBS, newer medications like lubiprostone and linaclotide for constipation, and alosetron and rifaximin for diarrhea, are enhancing therapeutic outcomes by targeting specific functional symptoms of the disorder.
Several factors are driving growth in the IBS therapeutics market. Advances in diagnostic technologies, such as the implementation of the Rome IV guidelines, have refined the accuracy of IBS diagnosis, fostering a more targeted therapeutic approach. There is also an increased consumer awareness and engagement, partly fueled by media, patient advocacy groups, and healthcare initiatives, which heighten demand for effective treatments. The integration of digital health solutions, including telehealth services and mobile health applications for symptom tracking and management, supports continuous patient monitoring and personalized treatment adjustments. Furthermore, the development of targeted pharmacological agents aimed at modifying gut flora, and expanding insurance coverage and healthcare policies that favor newer, albeit more costly, treatments are enhancing access to these therapies. These advancements, alongside active patient support programs and evolving regulatory landscapes, are essential for meeting the growing needs of IBS patients and improving their overall management and quality of life.
Report Scope
The report analyzes the Irritable Bowel Syndrome (IBS) Therapeutics market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.Segments: Type (IBS-D, IBS-C); Product (Linzess / Constella, Xifaxan, Viberzi, Amitiza, Other Products).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the IBS-D segment, which is expected to reach US$1.9 Billion by 2030 with a CAGR of a 6.9%. The IBS-C segment is also set to grow at 7.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $600.4 Million in 2024, and China, forecasted to grow at an impressive 11.4% CAGR to reach $791.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Irritable Bowel Syndrome (IBS) Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Irritable Bowel Syndrome (IBS) Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Irritable Bowel Syndrome (IBS) Therapeutics Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Allergan PLC, Astellas Pharma, Inc., IM HealthScience, Mallinckrodt Pharmaceuticals, Sebela Pharmaceuticals Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 12 companies featured in this Irritable Bowel Syndrome (IBS) Therapeutics market report include:
- Allergan PLC
- Astellas Pharma, Inc.
- IM HealthScience
- Mallinckrodt Pharmaceuticals
- Sebela Pharmaceuticals Inc.
- Takeda Pharmaceutical Co., Ltd.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allergan PLC
- Astellas Pharma, Inc.
- IM HealthScience
- Mallinckrodt Pharmaceuticals
- Sebela Pharmaceuticals Inc.
- Takeda Pharmaceutical Co., Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 269 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.3 Billion |
| Forecasted Market Value ( USD | $ 3.4 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
